Press Releases

Anti-Fibrotic Activity of Hepion Pharmaceuticals’ CRV431 Shows Potential to Extend to Multiple Organs and Fibrotic Diseases February 19, 2020
Hepion Pharmaceuticals Announces Advancement to Third Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431 February 12, 2020
Hepion’s NASH Drug Candidate, CRV431, Demonstrates Superior Antifibrotic Efficacy in Expanded Human Liver Study January 28, 2020
Hepion Pharmaceuticals Presents Update on CRV431 Nonclinical Studies at NASH-TAG 2020 Conference January 8, 2020
Hepion Pharmaceuticals Announces Publication in Expert Opinion on Investigational Drugs January 6, 2020
Hepion Pharmaceuticals Successfully Advances to Next Dosing Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431 December 10, 2019
Hepion Pharmaceuticals to Present Clinical and Scientific Updates at HEP DART 2019 December 9, 2019
Hepion Pharmaceuticals Announces Canadian Research Team’s Academic Appointments December 3, 2019
Hepion Pharmaceuticals to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference December 3, 2019
Hepion Pharmaceuticals' CRV431 Prevents Cirrhosis in Experimental Model of Severe Liver Disease November 20, 2019

Get Important News and Updates by Email Subscribe